Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast

Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast

ROCKVILLE, Md., May 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc.
(Nasdaq:SUPN), today announced that the Company expects to report financial
results for the quarter ended March 31, 2013 after the market closes on Monday
May 13, 2013. Supernus will host a conference call at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time) to review the financial results, as well as provide
an update on other business matters of the Company.

A live webcast will be available at webcast will be
archived on the Company's website for 30 business days following the live

Callers should dial in approximately 10 minutes prior to the start of the
call. The phone number to join the conference call is +1(877) 288-1043 (U.S.
and Canada) or +1 (970) 315-0267 (international and local). The access code
for the live call is 59547232.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has one marketed product for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one tentatively
approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The
Company is also developing several product candidates in psychiatry to address
large market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive aggression
in ADHD and SPN-812 for ADHD.

CONTACT: Jack Khattar, President and CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
Press spacebar to pause and continue. Press esc to stop.